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Aims The clinical characteristics, initial presentation, management, and outcomes of patients hospitalized with new-onset
(first diagnosis) heart failure (HF) or decompensation of chronic HF are poorly understood worldwide. REPORT-HF
(International REgistry to assess medical Practice with lOngitudinal obseRvation for Treatment of Heart Failure) is
a global, prospective, and observational study designed to characterize patient trajectories longitudinally during and
following an index hospitalization for HF.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Methods Data collection for the registry will be conducted at ∼300 sites located in ∼40 countries. Comprehensive data
including demographics, clinical presentation, co-morbidities, treatment patterns, quality of life, in-hospital and
post-discharge outcomes, and health utilization and costs will be collected. Enrolment of ∼20 000 adult patients
hospitalized with new-onset (first diagnosis) HF or decompensation of chronic HF over a 3-year period is planned
with subsequent 3 years follow-up.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Perspective The REPORT-HF registry will explore the clinical characteristics, management, and outcomes of HF worldwide. This
global research programme may have implications for the formulation of public health policy and the design and
conduct of international clinical trials.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Keywords Heart failure • Hospitalized • Global • Morbidity • Mortality • Quality of life
Introduction
Heart failure (HF) is a global public health problem affecting millions
worldwide.1–12 In the USA, the prevalence is 5.7 million and there
are 670 000 new cases per year, while there are another 15
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. million people living with HF in Europe.13–15 In addition, there
are >1 million admissions for HF annually in both the USA and
Europe, accounting for the vast majority spent each year on
HF-related care.13,14,16 However, the socio-economic burden of HF
is especially worrisome in the low- and middle-income regions of
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Africa, South America, the Middle East, and Asia Pacific, where the
prevalence of HF is rising rapidly and the clinical characteristics,
treatment patterns, and outcomes vary substantially.12,17–23
Several observational registries have been conducted in patients
with HF (Table 1).1–12 These registries have either focused on
in-patient characterization and short-term outcomes or main-
tained separate samples of acute HF hospitalizations and chronic
HF follow-up, limiting understanding of the transition from chronic
maintenance to an acute state requiring hospitalization.24,25 No
prior detailed, longitudinal evaluations of long-term disease pro-
gression, healthcare utilization, and health economics on a global
scale have been reported. Furthermore, while registries have been
conducted to compare within-region differences in disease charac-
teristics and outcomes, no truly international prospective registry
exists with uniform data collection and systematic follow-up using
a common protocol. In addition, most registries have been based
on non-consecutive enrolment, which may result in a sample that
is not representative of the real-world patient inflow. Clearly, there
remains an unmet clinical need in HF to design and conduct a geo-
graphically representative registry to shape public policy at all levels
and guide research endeavours.
Thus, REPORT-HF (International REgistry to assess medical
Practice with lOngitudinal obseRvation for Treatment of Heart
Failure), a global, prospective, and observational study initiated
during index hospitalization for new-onset (first diagnosis) HF or
decompensation of chronic HF designed to capture comprehensive
data on clinical characteristics, management, and outcomes with
longitudinal follow-up over 3 years, is proposed in order to enhance
the understanding of the epidemiology of HF worldwide.
Study design
Patients hospitalized with a primary diagnosis of new-onset (first
diagnosis) HF or decompensation of chronic HF as assessed by the
clinician–investigator are eligible for enrolment. Exclusion criteria
include current or recent participation in a clinical trial of any
investigational treatments. Each centre will implement an admission
log that will also document reasons for patients not being enrolled
in REPORT-HF. Each patient will be followed for 3 years or until
death, withdrawal of consent, or study termination.
Prospective enrolment will take place at ∼300 hospitals in
∼40 representative countries across Europe, North and Latin
America, Africa, Asia and the Pacific, and the Middle East (Figure 1).
The number of participating centres for each country takes into
consideration the size of its population. Investigators are asked to
recruit consecutive patients within assigned enrolment intervals
corresponding to an average of ∼70 patients over a period of
∼3 years. For smaller hospitals, this may translate into an open
enrolment to include all patients meeting inclusion criteria, while in
larger medical centres patients may be enrolled over a pre-defined
period in order to ensure that the workload is manageable and
that recruitment is evenly distributed across days of the week
and seasons of the year. The first patient was enrolled in July
2014 and, by end of 2014, ∼60 sites from 12 countries had been
initiated. ..
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.. Background HF therapy will be left to the discretion of the
treating physician, but all sites are encouraged to manage patients
according to standard local practice as informed by current
guideline-based recommendations. This study will be conducted in
accordance with the Declaration of Helsinki, the protocol submit-
ted and approved by the Institutional Review Board and/or ethics
committee at each participating centre, and written informed con-
sent obtained from all patients or a designated surrogate medical
decision-maker prior to enrolment.
Data collection and follow-up
The proposed time frame for data collection during hospitaliza-
tion and post-discharge is shown in Figure 2. Clinician–investigators
will enrol patients during the index admission and, with the
assistance of the study coordinator, will collect data on patient
demographics, past medical history (i.e. cardiac and non-cardiac
co-morbidities), admission and discharge medications, vital signs
and physical exam, laboratory values, acute management (i.e. HF-
and cardiovascular-related therapies and procedures), and hospital
course (i.e. in-hospital worsening HF and other adverse events).
Pre-specified data collection points will occur at 6months, 1 year,
and annually thereafter until study completion. At each data collec-
tion point, study staff will obtain an updated medical and medication
history, NYHA functional class, review of symptoms, vital status,
and interval events including invasive procedures, hospitalizations,
and scheduled and unscheduled office and emergency room vis-
its. Follow-up information from study participants will be collected
via telephone interviews unless a regular follow-up visit is planned
at the index site according to local practice. Every effort will be
made by the study personnel to obtain confirmation of the infor-
mation. In addition, vital status will be supplemented using national
reporting databases where available.
Patient and caregiver questionnaires
Validated questionnaires will optionally be completed at specific
time points to evaluate the quality of life (QOL) of the patient
and to assess the burden placed on the caregiver (Table 2). A
generic health status questionnaire [EuroQoL-5 Dimensions ques-
tionnaire (EQ-5D)]26 and a HF-specific questionnaire [Kansas City
CardiomyopathyQuestionnaire (KCCQ)]27 will be serially adminis-
tered to the patient. The EQ-5D is a widely used, self-administered
questionnaire designed to assess health status in adults. The tool
assesses five dimensions indicative of QOL (mobility, self-care,
usual activity, pain/discomfort, and anxiety/depression) and pro-
vides a self-rated global health status using a visual analogue scale
ranging from 0 (i.e. ‘worst possible health state’) to 100 (i.e. ‘best
possible health state’). On the day after admission (day 2), a special
(recall) version of the EQ-5D questionnaire will be administered
asking the patient to describe retrospectively how he or she felt
on the day of admission, while the standard EQ-5D questionnaire
will be administered on day 2 (in addition to the recall version)
and for the remainder of the study. The KCCQ tool is another
self-administered questionnaire covering physical activity, clinical
symptoms, social function, self-efficacy and knowledge, and QOL
© 2015 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 1 Planned countries participating in REPORT-HF.
Figure 2 Data collection time points.
each measured using a unique Likert scale. The KCCQ question-
naire is more extensive than the EQ-5D questionnaire and will only
be administered in select countries (i.e. Germany, Spain, Russia, the
UK, and the USA).
Similarly, the Work Productivity and Activity Impairment Ques-
tionnaire (WPAI)28 and the Caregiver Burden Questionnaire for
Heart Failure (CBQ-HF)29 will be utilized to assess the burden
placed on the caregiver. The WPAI includes six items that mea-
sure absenteeism, presenteeism, lost work productivity, and activ-
ity impairment. In contrast, the CBQ-HF consists of four domains
measuring the impact of caring for HF patients on aspects of the ..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.. caregiver’s daily life including physical well-being, emotional health,
social life and relationships, and lifestyle.
Statistical analysis plan
A sample size of 20 000 participants has been proposed to estimate
comparisons of interest and taking into account potential losses
to follow-up. In order to perform meaningful analyses comparing
proportions across clinically relevant subgroups (i.e. defined by
combinations of geographic area, type of admission unit, clinical
characteristics, etc.), a sample size of 300 in each of the strata will
© 2015 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 2 Administration time points of patient and caregiver questionnaires
Questionnaires Administration time points
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Index hospitalization Follow-up data capture points
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Day 2 Day 5 Discharge 6months 1 year 2 year 3 year
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Patient EQ-5D Xa X X X X X X
KCCQb X X X X X
Caregiver CBQ-HFc X X X X X
WPAIc X X X X X
EQ-5D, [EuroQoL-5 Dimensions questionnaire; KCCQ, Kansas City Cardiomyopathy Questionnaire; CBQ-HF, Caregiver Burden Questionnaire–Heart Failure; WPAI, Work
Productivity and Activity Impairment Questionnaire.
aEQ-5D administration on Day 2 with additional recall for admission day.
bAdministered only in selected countries.
cAdministered only in English-speaking countries.
enable pairwise comparisons to detect a margin of difference of up
to 10%. The target sample size will be re-evaluated when ∼50% of
patients have been recruited. A full description of data status will
be provided to the steering committee in periodic reports. Missing
or incomplete data will be addressed using imputation algorithms
along with sensitivity analyses.
The primary analysis will describe the geographic variation in
clinical characteristics, management, hospital course during index
admission, and long-term health resource utilization (HRU; i.e.
scheduled and unscheduled office appointments, emergency room
visits, and hospitalizations) and survival. Secondary analyses will
be performed to evaluate patient QOL and caregiver burden. In
addition, the associations between patient management strategies
and HRU will be assessed. Finally, a disease model will be created
combining clinical outcomes and disease status data to improve our
understanding of disease pathophysiology and progression as well
as relevant drivers of HRU.
Discussion
Heart failure is a global public health problem and socio-economic
burden, which may be at least partially attributable to a poor
understanding of this heterogeneous syndrome.24,25 Although
disease-based registries remain the primary source of real-world
data on chronic medical conditions and fundamental to shaping
public health policy at all levels and guiding research from bench
to bedside, limitations of the available registry data include, but are
not limited to, poor geographic representation, non-consecutive
patient enrolment, incomplete data capture, and absent or short
duration of follow-up. REPORT-HF is a global, prospective, and
observational registry initiated during the index HF hospitaliza-
tion with longitudinal patient follow-up of up to 3 years aiming to
advance the comprehension of the epidemiology of HF worldwide.
There are several salient features of this observational study
which merit further mention. REPORT-HF is the first truly global
observational experience in HF, with ∼300 centres in ∼40 rep-
resentative countries across Europe, North and Latin America,
Africa, Asia and the Pacific, and the Middle East. In contrast, .
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. prior large-scale HF registries have primarily enrolled patients in
North America andWestern Europe, collectively representing only
slightly more than 15% of the world’s population. In addition, pre-
vious observational experiences in HF have primarily relied on
non-consecutive enrolment of patients admitted with an unequiv-
ocal primary diagnosis of HF, which may have led to a non-random
sampling of lower acuity patients. Thus, this study will employ con-
secutive or intermittently consecutive enrolment in order to obtain
a representative cohort while minimizing the workload required of
study personnel.
Although data collection in registries is often limited by resource
availability and variation in routine clinical practice, REPORT-HF
will utilize a standard protocol and case report form across all cen-
tres including follow-up in order to provide a detailed description
of clinical characteristics and management of HF patients of all lev-
els of acuity, across the spectrum of clinical settings, and over time.
In addition, REPORT-HF will provide insights into the initiation and
titration of guideline-directed medical therapies over time includ-
ing the initial real-world experience with promising and emerging
treatment options. Most importantly, REPORT-HF will for the first
time serially track outcomes including HRU (i.e. scheduled and
unscheduled office appointments, emergency room visits, and hos-
pitalizations), patient QOL and caregiver burden, and survival over
a time frame of years in a geographically diverse and representative
population.
In an era of globalization in cardiovascular research, the most sig-
nificant contribution of REPORT-HF may be to the future design
and conduct of international clinical trials, which have traditionally
suffered from poor enrolment. Interestingly, post-hoc analyses of
phase III clinical trial databases have found substantial geographic
variation in the aetiology of HF, co-morbid disease states, back-
ground therapy, and event rates (i.e. hospitalizations and mortality)
despite employing specific inclusion and exclusion criteria to select
for a relatively homogeneous and enriched study population.30,31
Furthermore, there is a growing appreciation among the scien-
tific community that failure to consider these regional differences
in patient characteristics, management, and outcomes at the plan-
ning stage may impact both the response to therapy and the suc-
cess or failure of pivotal trials.32,33 Thus, REPORT-HF provides
© 2015 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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the opportunity to preview patient characteristics and document
heterogeneity in patient management as well as its clinical conse-
quences at participating centres. In addition, the findings from this
study may provide insights into the operational aspects of global
clinical trials including, but not limited to, assessing potential sites
for enrolment capacity, refining inclusion and exclusion criteria, and
selecting endpoints.34
There are several limitations of the data inherent to the conduct
of a large-scale international registry. First, patients will be enrolled
at the point-of-care by clinician–investigators based on their judge-
ment without central validation. Although this raises the potential
for misclassification, diagnostic criteria for HF will be discussed
at investigator meetings. HF remains a challenging clinical diagno-
sis and there is no clear definition for an ‘acute’ episode of care
or criteria for hospital admission. Secondly, although the proto-
col is designed to facilitate data collection and minimize workload,
there will inevitably be missing data and patients lost to follow-up.
However, every effort will be made to contact patients, their care-
givers, and/or treating physicians, and, where applicable, medical
records will be obtained. In addition, statistical approaches for
imputation accounting for observational uncertainty and borrow-
ing from observed data will be used to mitigate the issue of missing
data. Finally, since this study is observational in nature, informa-
tion on all outcomes might not be available from recall, and for
those recorded outcomes there will be no independent adjudica-
tion. However, this study will include an unprecedented follow-up
duration of 3 years linking the initial acute hospitalization with sub-
sequent clinical events, and vital status will be supplemented using
national reporting databases where applicable.
There is currently an unmet clinical need in HF to design and
conduct a global registry to facilitate a clearer understanding of this
heterogeneous patient population, inform public policy decisions,
and guide clinical research efforts. REPORT-HF is an international
registry of patients hospitalized with new-onset (first diagnosis) HF
or decompensation of chronic HF that is diverse and geographically
representative, employs consecutive or intermittently consecutive
enrolment, and captures comprehensive and longitudinal data on
clinical characteristics, management, and outcomes. This study
aims to enhance the current understanding of HF worldwide and
may have implications for the future design and conduct of quality
improvement initiatives and clinical trials.
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